2-methyl-1-(2,2,3,3-tetramethyl-cyclopropyl)-propan-1-one | 32117-22-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-methyl-1-(2,2,3,3-tetramethyl-cyclopropyl)-propan-1-one
• 英文别名: Isopropyl-2,2,3,3-tetramethyl-cyclopropylketon；2-Methyl-1-(2,2,3,3-tetramethylcyclopropyl)propan-1-one；2-methyl-1-(2,2,3,3-tetramethylcyclopropyl)propan-1-one
• CAS: 32117-22-9
• 化学式: C₁₁H₂₀O
• 分子量: 168.279
• InChiKey: FGSDJIAZJBEVQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,3-二甲基-2-丁烯 在 硫酸 、 potassium tert-butylate 、 水 作用下， 以 四氢呋喃 为溶剂， 生成 2-methyl-1-(2,2,3,3-tetramethyl-cyclopropyl)-propan-1-one
  参考文献：
  名称：

  Electrophilic additions to 2-methyl-1-(tetramethylcyclopropylidene) propene. Generation of cyclopropylidenecarbinyl cations

  摘要：

  DOI：

  10.1021/ja00731a023

文献信息

• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20130183269A1

  公开（公告）日：2013-07-18

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组成物，以及抑制NS5A蛋白功能的方法。
• HEPATITIS C VIRUS INHIBITORS
  申请人：BRISTOL-MAYERS SQUIBB COMPANY

  公开号：US20160199355A1

  公开（公告）日：2016-07-14

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合、包含这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• Combinations of Hepatitis C Virus Inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160158200A1

  公开（公告）日：2016-06-09

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包含这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20180057505A1

  公开（公告）日：2018-03-01

  The compounds of formula I, wherein the variables are as defined herein, and pharmaceutically acceptable salts thereof are useful as inhibitors of the PAR-2 signaling pathway. The compounds of formula I and pharmaceutically acceptable compositions comprising such compounds can be employed for treating various diseases, disorders, and conditions.
• US9326973B2
  申请人：——

  公开号：US9326973B2

  公开（公告）日：2016-05-03